Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hour.
Acknowledgment of Support
This activity is supported by educational grants from: Akebia Therapeutics Inc., AstraZeneca, Pfizer-Merck Alliance.
Community Practice Connections: 4th Annual Cardio-Endo-Renal Collaborative
Release Date: November 13, 2020
Expiration Date: November 13, 2021
The ever-increasing presence of cardiometabolic risk factors continues to be a major challenge for health care providers in the US. Current estimates suggest that approximately 23% to 38% of all US adults have metabolic syndrome, a constellation of cardiometabolic risk factors that includes excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. These risk factors converge with chronic inflammation, hypercoagulation, and certain genetic traits to the detriment of patient health. Patients with metabolic syndrome have a 3- to 5-fold higher risk of developing diabetes and at least double the risk of cardiovascular disease (CVD) and stroke. Other CVD consequences, such as acute coronary syndrome (ACS), thrombosis, and atrial fibrillation, have also been linked to metabolic syndrome. In addition, patients with multiple cardiometabolic risk factors commonly suffer comorbidities that can exacerbate CVD risk and negatively affect quality of life.
This online education activity provides expert perspectives on managing patients with cardiometabolic risk factors. Given the prevalence of cardiometabolic diseases and the scope of the problem, there is great need to bring scientific breakthroughs and clinical updates to a multidisciplinary mix of specialty clinicians. Specialty physicians and allied health professionals are optimally positioned to combat the increasing prevalence of cardiometabolic syndrome by addressing prevention and risk reduction, designing treatment and monitoring regimens, and providing patient education. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.
Acknowledgement of Commercial Support
This activity is supported by educational grants from: Akebia Therapeutics Inc., AstraZeneca, and Pfizer-Merck Alliance.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward cardiologists, endocrinologists, specialty nurse practitioners, specialty physician assistants, certified diabetes educators, other specialty allied health professionals, nephrologists, and other health care professionals.
Upon successful completion of this activity, you should be better prepared to:
- Discuss clinical strategies for the evaluation and diagnosis of patients presenting with cardiac, endocrine, and renal disease
- Discern the potential clinical impact of recent clinical trial data on the management of cardiac, endocrine, and renal disease
- Identify current strategies and recent advances in the prevention of cardiometabolic disorders
- Employ strategies for patient counseling to improve education, preventive practices, adherence, and self-management
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Executive Vice President for Education
Primary Care Education Consortium
Adjunct Associate Clinical Professor
Department of Family Medicine
Touro University California
Disclosures: Consultant: Abbott, AstraZeneca, Janssen, Bayer, Novo Nordisk, Sanofi, Xeris Pharmaceuticals; Speakers Bureau: Novo Nordisk, Sanofi, Xeris Pharmaceuticals, Bayer, Eli Lilly and Company
Gerald S. Berenson Chair in Preventative Cardiology
Professor of Clinical Medicine
Tulane University Heart and Vascular Institute
New Orleans, LA
Disclosures: Consultant: Amgen, Sanofi, Boehringer Ingelheim, Janssen, Quantum Genomics
Past President, National Lipid Association
Clinical Assistant Professor of Medicine
New York University Grossman School of Medicine
New York, NY
Disclosures: Grant Research Support: Aegerion Pharmaceuticals, Pfizer; Consultant: Amarin, Amgen; Speakers Bureau: Amgen, Amarin, Akcea Therapeutics, Alexion Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals; Other: Advisory Boards: Amgen, Sanofi, Regeneron Pharmaceuticals, Akcea Therapeutics, Aegerion Pharmaceuticals, Alexion Pharmaceuticals, Ambry Genetics
Director, Division of Nephrology
Department of Medicine
University of Maryland Hospital
Professor of Medicine
University of Maryland School of Medicine
Disclosures: Grant Research Support: National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases; Consultant: Janssen, Vifor Pharma, Relypsa, Boehringer Ingelheim, AstraZeneca, Akiloa, Boston Scientific, Merck Sharp & Dohme
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.